Cipla Gets Nod for Insulin Inhalation Powder: Afrezza
By Rediff Money Desk, New Delhi Dec 11, 2024 17:34
Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution for diabetes management in India. The drug is the first and only non-injectable insulin for both type 1 and type 2 diabetes.
New Delhi, Dec 11 (PTI) Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.
Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus.
By bringing a game-changing, patient-centred solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement.
Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections.
Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream.
Afrezza starts working as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals.
The effect of the drug lasts for about 2-3 hours and it closely resembles the body's response to insulin.
This is the first and only non-injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus, the drug firm said.
"By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively," Cipla MD and Global CEO Umang Vohra said.
Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus.
By bringing a game-changing, patient-centred solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement.
Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections.
Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream.
Afrezza starts working as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals.
The effect of the drug lasts for about 2-3 hours and it closely resembles the body's response to insulin.
This is the first and only non-injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus, the drug firm said.
"By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively," Cipla MD and Global CEO Umang Vohra said.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.99 (+ 1.52)
- 58018780
- Mishtann Foods L
- 9.17 ( -5.17)
- 27555831
- Shree Securities
- 0.42 ( -6.67)
- 27309223
- AvanceTechnologies
- 0.90 ( -4.26)
- 25537567
- Rajnish Wellness
- 1.69 ( -2.87)
- 19267607
MORE NEWS
Zepto Cuts Losses, Revenue Doubles in FY24
Quick commerce firm Zepto narrowed its losses to Rs 1,248.6 crore in FY24, while...
KKR Sells 2.6% Stake in India Grid Trust for Rs...
Private equity firm KKR has sold a 2.6% stake in India Grid Trust for Rs 277 crore...
MFN Clause Suspension: India Needs Strategic...
Switzerland's suspension of the MFN clause in its tax treaty with India highlights the...